Tumor genomic analysis showed higher FGFR3 alterations in UTUC patients, and these patients could potentially benefit from FGFR3-targeted therapy.33 Patients with bladder urothelial carcinoma had higher PD-L1 than those with UTUC and thus were more likely to benefit from immunotherapy.33 This evidence concerns the gene FGFR3 and renal pelvis/ureter urothelial carcinoma.